MetaCap

ArriVent BioPharma Earnings

NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

10.52-0.74 (-6.57%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ArriVent BioPharma earnings summary

In its most recent report on Nov 9, 2026 (Sep/2026), AVBP posted EPS of $-0.81 versus the $-1.04 consensus estimate, a positive surprise of 22.1%. Revenue for the quarter was $5.0 million. Across the last 11 reports, AVBP shares moved an average of 5.0% (in either direction) in the first trading session after results, rising 5 times and falling 6 times.

Summary generated from market data by MetaCap's automated system. Methodology

AVBP earnings history

ArriVent BioPharma reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Nov 9, 2026$-1.04$-0.81+22.1%-19.1%
Aug 12, 2026—$-1.05—-1.3%
May 11, 2026—$-0.96—-4.1%
Mar 5, 2026—$-0.69—+2.0%
Nov 10, 2025—$-0.83—-1.6%
Aug 11, 2025—$-0.90—+3.0%
May 12, 2025—$-1.90—+5.4%
Mar 3, 2025—$-0.60—-4.0%
Nov 14, 2024—$-0.61—+0.9%
Aug 14, 2024—$-0.65—-0.4%
May 8, 2024—$-0.70—+13.6%

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related